PLRX
Pliant Therapeutics, Inc. NASDAQ Listed Jun 3, 2020$1.24
Mkt Cap $76.8M
52w Low $1.09
17.4% of range
52w High $1.95
50d MA $1.28
200d MA $1.42
P/E (TTM)
-0.5x
EV/EBITDA
-0.4x
P/B
0.4x
Debt/Equity
0.2x
ROE
-82.4%
P/FCF
-0.6x
RSI (14)
—
ATR (14)
—
Beta
1.25
50d MA
$1.28
200d MA
$1.42
Avg Volume
655.6K
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
260 Littlefield Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | -0.42 | -0.35 | +16.7% | 1.33 | +0.0% | +6.0% | -4.3% | -3.0% | +1.5% | -3.8% | — |
| Nov 6, 2025 | AMC | -0.53 | -0.43 | +18.9% | 1.53 | -1.3% | +4.6% | +1.2% | +3.1% | +7.8% | -4.4% | — |
| Aug 7, 2025 | AMC | -0.62 | -0.71 | -14.5% | 1.68 | -7.1% | -1.2% | +2.4% | -1.2% | -4.8% | -1.2% | — |
| May 8, 2025 | AMC | -0.78 | -0.92 | -17.9% | 1.46 | -0.7% | -3.4% | +4.3% | -6.1% | -1.4% | +0.7% | — |
| Mar 3, 2025 | AMC | -0.99 | -0.82 | +17.2% | 1.38 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% | — |
| Nov 7, 2024 | AMC | -0.99 | -0.95 | +4.0% | 15.19 | +0.1% | -1.3% | -3.3% | -4.8% | -0.4% | -6.7% | — |
| Aug 7, 2024 | AMC | -0.85 | -0.92 | -8.2% | 12.54 | +0.5% | -2.2% | +0.2% | -3.5% | +3.5% | -2.8% | — |
| May 6, 2024 | AMC | -0.76 | -0.78 | -2.6% | 13.79 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% | — |
| Feb 27, 2024 | AMC | -0.81 | -0.69 | +14.8% | 17.21 | +4.6% | -3.4% | -4.5% | +4.2% | -0.9% | -1.0% | — |
| Nov 9, 2023 | AMC | -0.78 | -0.70 | +10.3% | 14.20 | +10.0% | -2.6% | -7.1% | +2.5% | +3.3% | -0.7% | — |
| Aug 9, 2023 | AMC | -0.73 | -0.70 | +4.1% | 18.18 | +1.2% | +3.3% | -4.0% | -0.1% | -0.4% | -4.1% | — |
| May 9, 2023 | AMC | -0.66 | -0.67 | -1.5% | 22.51 | +1.6% | +2.3% | -1.6% | -2.5% | +1.1% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | Canaccord Genuity | Maintains | Hold → Hold | — | $1.41 | $1.41 | +0.0% | -4.3% | -3.0% | +1.5% | -3.8% | +3.9% |
| Mar 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.33 | $1.33 | +0.0% | +6.0% | -4.3% | -3.0% | +1.5% | -3.8% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.53 | $1.51 | -1.3% | +4.6% | +1.2% | +3.1% | +7.8% | -4.4% |
| Oct 10 | JP Morgan | Downgrade | Neutral → Underweight | — | $1.54 | $1.48 | -3.9% | -4.5% | +1.4% | +1.3% | +4.0% | +5.1% |
| Aug 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.68 | $1.56 | -7.1% | -1.2% | +2.4% | -1.2% | -4.8% | -1.2% |
| Mar 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.70 | $1.65 | -2.9% | -0.6% | -4.1% | -2.5% | -1.9% | +2.6% |
| Mar 4 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 4 | Needham | Downgrade | Buy → Hold | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 3 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $3.44 | $3.10 | -9.9% | -59.9% | -2.2% | +12.6% | +3.9% | +2.5% |
| Feb 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.29 | $3.15 | -4.3% | -7.6% | -2.0% | +0.7% | +0.3% | +2.3% |
| Feb 14 | Needham | Maintains | Buy → Buy | — | $3.29 | $3.15 | -4.3% | -7.6% | -2.0% | +0.7% | +0.3% | +2.3% |
| Feb 10 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | Citigroup | Downgrade | Buy → Neutral | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | JP Morgan | Downgrade | Overweight → Neutral | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | Canaccord Genuity | Downgrade | Buy → Hold | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | Needham | Maintains | Buy → Buy | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.19 | $15.21 | +0.1% | -1.3% | -3.3% | -4.8% | -0.4% | -6.7% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.84 | $12.01 | +1.4% | +1.4% | -1.1% | +6.1% | -0.8% | +1.0% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.28 | $12.05 | -1.9% | -3.5% | +3.5% | -2.8% | +4.2% | +1.0% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $12.54 | $12.60 | +0.5% | -2.2% | +0.2% | -3.5% | +3.5% | -2.8% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.54 | $12.60 | +0.5% | -2.2% | +0.2% | -3.5% | +3.5% | -2.8% |
| Jul 16 | Needham | Maintains | Buy → Buy | — | $13.23 | $13.38 | +1.1% | +2.0% | -4.7% | -3.2% | -0.7% | +1.4% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.23 | $13.38 | +1.1% | +2.0% | -4.7% | -3.2% | -0.7% | +1.4% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.54 | $11.20 | -2.9% | -3.4% | +3.2% | -1.9% | +4.2% | +1.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.14 | $14.56 | +3.0% | +8.6% | +1.6% | -2.2% | -1.0% | -3.5% |
| May 7 | Needham | Maintains | Buy → Buy | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| May 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| May 7 | Citigroup | Maintains | Buy → Buy | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $14.92 | $14.34 | -3.9% | -5.2% | +2.3% | -2.2% | -4.2% | -2.1% |
| Mar 12 | Needham | Maintains | Buy → Buy | — | $14.53 | $14.53 | +0.0% | +4.2% | +1.6% | -3.1% | +1.9% | -3.9% |
| Mar 5 | RBC Capital | Maintains | Outperform → Outperform | — | $16.39 | $16.59 | +1.2% | -1.0% | -3.3% | -0.3% | -0.6% | -6.6% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.21 | $18.00 | +4.6% | -3.4% | -4.5% | +4.2% | -0.9% | -1.0% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $17.21 | $18.00 | +4.6% | -3.4% | -4.5% | +4.2% | -0.9% | -1.0% |
| Feb 28 | RBC Capital | Maintains | Outperform → Outperform | — | $17.21 | $18.00 | +4.6% | -3.4% | -4.5% | +4.2% | -0.9% | -1.0% |
| Feb 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.40 | $16.77 | -3.6% | -9.2% | +2.0% | -0.9% | +2.0% | +3.9% |
| Feb 5 | Needham | Maintains | Buy → Buy | — | $17.40 | $16.77 | -3.6% | -9.2% | +2.0% | -0.9% | +2.0% | +3.9% |
| Nov 10 | RBC Capital | Maintains | Outperform → Outperform | — | $14.20 | $15.62 | +10.0% | -2.6% | -7.1% | +2.5% | +3.3% | -0.7% |
| Oct 4 | Needham | Maintains | Buy → Buy | — | $17.06 | $16.99 | -0.4% | -3.2% | +4.8% | +1.7% | -3.0% | +1.2% |
| Sep 27 | Needham | Maintains | Buy → Buy | — | $16.67 | $17.04 | +2.2% | -0.7% | -1.0% | +5.7% | -7.4% | +6.3% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.67 | $17.04 | +2.2% | -0.7% | -1.0% | +5.7% | -7.4% | +6.3% |
| Sep 15 | Needham | Maintains | Buy → Buy | — | $16.18 | $16.21 | +0.2% | -1.1% | +2.4% | +1.2% | -1.6% | -2.4% |
| Aug 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.55 | $16.61 | +0.4% | +0.2% | +0.7% | +1.0% | -0.5% | +0.1% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.17 | $17.17 | +0.0% | -0.9% | -0.2% | -2.8% | -1.6% | +1.8% |
No insider trades available.
8-K · 5.02
!!! Very High
Pliant Therapeutics, Inc. -- 8-K 5.02: Executive Change
Pliant Therapeutics director Pyott retired from the board due to personal reasons, with no operational disagreements, suggesting stable corporate governance and continuity.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
PLRX disclosed a material event via 8-K filing, though specific details aren't provided in this summary, making it impossible to assess the stock impact without reviewing the complete filing.
Mar 30
8-K
Unknown — 8-K Filing
PLN-101095's positive Phase 1 data in difficult-to-treat tumors validates Pliant's integrin approach and accelerated Phase 1b expansion could create near-term catalysts, potentially justifying higher valuations.
Mar 11
8-K · 1.01
! Medium
Pliant Therapeutics, Inc. -- 8-K 1.01: Governance / Corporate
Pliant Therapeutics appointed Computershare Trust Co. as transfer agent, a routine administrative change that facilitates stock transfer and shareholder record-keeping operations.
Mar 3
Data updated apr 26, 2026 7:57pm
· Source: massive.com